ArticleMedicine2026
Global, regional and national burden of skin cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2035.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is among the most common malignancies worldwide, mainly classified into malignant skin melanoma (MSM) and nonmelanoma skin cancer (NMSC). This study aimed to comprehensively analyze the global burden and temporal trends of skin cancer, focusing on the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021. Data on incidence, mortality, and disability-adjusted life years (DALYs) for skin cancer were obtained from the Global Burden of Disease 2021 database across 204 countries and territories. Both crude numbers and age-standardized rates (ASIR, ASMR, and ASDR) were analyzed. Temporal trends were evaluated using estimated annual percentage change, and autoregressive integrated moving average (ARIMA) models were applied to project age-standardized rates, rather than crude counts, through 2035. In 2021, there were 3,03,105 MSM cases, 18,99,907 squamous cell carcinoma cases, and 44,36,939 basal cell carcinoma cases globally. From 1990 to 2021, the global ASIR of MSM increased by 19.32% (95% UI: 13.60-23.62%), squamous cell carcinoma by 67.34% (95% UI: 42.13-95.42%), and basal cell carcinoma by 63.30% (95% UI: 52.54-77.53%). High-SDI regions showed the highest incidence levels, whereas middle-SDI regions bore relatively higher mortality and DALY burdens. Males consistently exhibited higher incidence, mortality, and DALYs than females, and the disease burden increased markedly with age, particularly among individuals aged ≥ 70 years. ARIMA projections suggest subtype-specific trends, with age-standardized incidence and DALY rates remaining stable or declining for most skin cancer subtypes through 2035. Significant regional disparities persist in the burden of skin cancer. While high-income regions report higher incidence, low-income regions face greater challenges in early detection and treatment. Strengthening UV protection awareness, promoting early screening, and improving healthcare access are essential to reduce the future global burden of skin cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.